https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Adjuvant exemestane with ovarian suppression in premenopausal breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:16287 Wed 11 Apr 2018 11:53:01 AEST ]]> Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:34779 Thu 31 Oct 2019 16:13:17 AEDT ]]> Systemic treatment of HER2-positive metastatic breast cancer: a systematic review https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20551 Sat 24 Mar 2018 08:02:39 AEDT ]]> Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:23759 Sat 24 Mar 2018 07:11:09 AEDT ]]> Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19927 Mon 06 Aug 2018 11:18:23 AEST ]]> Tumor-infiltrating lymphocytes and prognosis: a poled individual patient analysis of early-stage triple-negative breast cancers https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:34339 Mon 03 Feb 2020 11:52:07 AEDT ]]>